Dr. Scagliotti on the Benefits of EGFR Targeted Therapy

Giorgio V. Scagliotti, MD, PhD
Published: Tuesday, Sep 27, 2011

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, stresses the importance of testing and treating non-small cell lung cancer (NSCLC) patients based on the epidermal growth factor receptor (EGFR) mutation.

The average survival benefit experienced by NSCLC patients treated with the EGFR targeted therapies erlotinib and gefitinib, in either the first or second-line, was around 24 months. Scagliotti explains that before the use of the EGFR-mutation in NSCLC it was impossible to achieve this type of survival benefit.

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, stresses the importance of testing and treating non-small cell lung cancer (NSCLC) patients based on the epidermal growth factor receptor (EGFR) mutation.

The average survival benefit experienced by NSCLC patients treated with the EGFR targeted therapies erlotinib and gefitinib, in either the first or second-line, was around 24 months. Scagliotti explains that before the use of the EGFR-mutation in NSCLC it was impossible to achieve this type of survival benefit.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x